Cambrex (NYSE: CBM) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Cambrex to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Cambrex and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cambrex 18.79% 23.42% 16.19%
Cambrex Competitors -2,404.13% -72.13% -8.16%

Analyst Ratings

This is a summary of current ratings and recommmendations for Cambrex and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambrex 0 0 3 0 3.00
Cambrex Competitors 873 3800 6786 181 2.54

Cambrex presently has a consensus target price of $62.33, suggesting a potential upside of 25.55%. As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given Cambrex’s stronger consensus rating and higher probable upside, equities analysts clearly believe Cambrex is more favorable than its peers.

Insider and Institutional Ownership

44.1% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.5% of Cambrex shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Cambrex has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Cambrex’s peers have a beta of 35.17, indicating that their average share price is 3,417% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cambrex and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cambrex $490.64 million $81.67 million 16.55
Cambrex Competitors $8.17 billion $1.09 billion 141.27

Cambrex’s peers have higher revenue and earnings than Cambrex. Cambrex is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Cambrex peers beat Cambrex on 7 of the 13 factors compared.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.